Companies / Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
Financials · FY2025
Ownership
445.0M shares outstanding · as of Aug 3, 2026
Ownership
| Insiders | 40.83% | 181,670,606 |
| Institutions | 67.81% | 301,707,227 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 26
View all →| Insider | % of shares | Shares |
|---|---|---|
Artal Participations S.a r.l.Director · 10% owner | 39.36% | 175,156,062 |
Debbane RaymondDirector | 0.45% | 1,995,498 |
Invus, L.P.Director · 10% owner | 0.35% | 1,538,462 |
Crum Brian TSVP, General Counsel & Secr. | 0.10% | 428,802 |
Amouyal PhilippeDirector | 0.08% | 374,486 |
Granowitz Craig BSVP, Chief Medical Officer | 0.07% | 323,430 |
Exton MichaelCEOChief Executive Officer · Director | 0.07% | 298,432 |
Sobecki Christopher JDirector | 0.07% | 293,177 |
McDermott WendySVP, Human Resources | 0.06% | 277,945 |
Barker Sam LDirector | 0.05% | 213,771 |
Institutional holders 133
View all →| Holder | Value | % of shares |
|---|---|---|
| $241.39M | 34.78% | |
| $44.76M | 8.75% | |
| $43.51M | 8.50% | |
| $41.64M | 3.90% | |
| $11.80M | 1.11% | |
| $11.05M | 2.16% | |
| $7.71M | 1.11% | |
| $4.95M | 0.71% | |
| $3.71M | 0.53% | |
| $3.46M | 0.68% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $33.98M | +14.2M +443.43% | 17,348,741 3.90% of shares | medium |
| Q1 2026 as of | Artal Group S.A. 13F manager | Add | Common Stock | $28.94M | +18.6M +13.62% | 154,734,327 34.78% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $9.68M | +4.0M +455.84% | 4,917,769 1.11% of shares | medium |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Add | Common Stock | $2.09M | +1.3M +507.97% | 1,600,500 0.36% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | Common Stock | $1.74M | +1.1M +88.24% | 2,376,304 0.53% of shares | low |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | Common Stock | $1.04M | +669K +26.76% | 3,169,111 0.71% of shares | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Add | Common Stock | $877.2K | +562K +88.23% | 1,199,632 0.27% of shares | low |
| Q1 2026 as of | Tang Capital Management, LLC 13F manager | New | Common Stock | $623.5K | +400K | 399,700 0.09% of shares | low |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| LXRX | Common Stock | 528872302 |